UNICYCIVE THERAPEUTICS INC (UNCY)
US90466Y1038 - Common Stock
UNICYCIVE THERAPEUTICS INC
NASDAQ:UNCY (6/28/2024, 7:00:01 PM)
After market: 0.514 +0.01 (+2.57%)0.5011
+0.1 (+23.7%)
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 12 full-time employees. The company went IPO on 2021-06-17. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis (CKD), and UNI 494, for treatment of acute kidney injury (AKI). Renazorb is initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum). UNI 494 is initially developed by and licensed to it from Sphaera Pharmaceuticals, respectively.
Company Info
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA
P: 16503840642
CEO: Shalabh Gupta
Employees: 12
Website: https://unicycive.com/
UNCY News
5 days ago - ChartmillWhat's going on in today's sessionTop movers analysis one hour before the close of the markets on 2024-06-25: top gainers and losers in today's session.
5 days ago - ChartmillWhat's going on in today's sessionLooking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
5 days ago - Unicycive Therapeutics, Inc.Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and...
9 days ago - ChartmillFriday's after hours session: top gainers and losersThe regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
a month ago - Unicycive Therapeutics, Inc.Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in...
a month ago - Unicycive Therapeutics, Inc.Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceLOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
UNCY Twits
Here you can normally see the latest stock twits on UNCY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
